Beractant (equiv to phospholipids 25 mg/mL, triglycerides 0.5-1.75 mg/mL, free fatty acids 1.4-3.5 mg/mL, proteins <1 mg/mL)
Prevention & treatment of resp distress syndrome (RDS) in premature infants.
4 mL/kg birth wt via endotracheal tube. 4 doses can be administered in the 1st 48 hr of life. Doses should be given no more frequently than 6 hrly.
Infants <600 g birthwt. For intratracheal use only.
Transient bradycardia. O
2 desaturation.
View
Survanta description for details of the chemical structure and excipients (inactive components).
R07AA02 - natural phospholipids ; Belongs to the class of lung surfactants. Used in the treatment of respiratory diseases.
R07AA30 - combinations ; Belongs to the class of lung surfactants. Used in the treatment of respiratory diseases.
Survanta intratracheal susp 25 mg/mL
(vial) 8 mL x 1's;4 mL x 1's
Sign Out
